Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70129 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Sung-Chun Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Center and Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Pyridines, Thiazoles, Factor Xa Inhibitors, Atrial Fibrillation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council, Taiwan, Ministry of Education for financial assistance, Taiwan, National Taiwan University Hospital.
Abstract (Originalsprache)
This study investigated real‐world edoxaban concentrations across different dosing regimens, with a specific focus on patients who met the inclusion criteria of low‐dose edoxaban for the Elder Care Atrial Fibrillation (ELDERCARE‐AF) trial. Patients with atrial fibrillation receiving edoxaban were enrolled to measure trough concentrations. The levels were compared with the expected therapeutic range (12–43 ng/mL) to define low or high concentrations. Data on ischemic stroke and systemic thromboembolism (SSE), and major bleeding, were collected prospectively. In total, 402 patients (77.2 ± 10.6 years; 52.2% men) were included. The SSE incidence was 1.22 (0.56–2.31) per 100 person years and was significantly associated with low edoxaban concentration (aHR, 4.13 [1.08–15.82]). Among patients meeting the ELDERCARE‐AF criteria ( n = 160), the use of the 15‐mg regimen (ELDER‐15 mg, n = 46) vs. the 30‐mg regimen (ELDER‐30 mg, n = 114) (aOR, 7.65 [2.92–20.09]), higher creatinine clearance (CrCL) (aOR, 1.05 [1.01–1.08]) and lower CHA 2 DS 2 ‐VA score (aOR, 0.69 [0.51, 0.95]) were significantly associated with low concentrations. In the ELDER‐15 mg group, patients with CrCL > 50 mL/min had more than 50% probability of exhibiting low drug concentrations. The incidence of SSE was numerically higher in the ELDER‐15 mg group than the ELDER‐30 mg group (2.34 [0.06–13.02] vs. 1.55 [0.32–4.52]), while major bleeding rates were similar (4.67 [0.57–16.89] vs. 5.15 [2.47–9.48]). In conclusion, low edoxaban concentrations have been associated with thromboembolic events. Among ELDERCARE‐AF‐eligible patients, the 15‐mg regimen results in underexposure to edoxaban, particularly when the CrCL exceeded 50 mL/min.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Stroke Center and Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
- School of Pharmacy, National Taiwan University, Taipei, Taiwan.
- Division of Cardiovascular Center, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Sung-Chun Tang, Shin-Yi Lin, Chih-Hao Chen, Yen-Bin Liu, Li-Ting Ho, Ching-Hua Kuo, Chih-Fen Huang, Jiann-Shing Jeng
Förderung
- National Science and Technology Council, Taiwan
- Ministry of Education for financial assistance, Taiwan
- National Taiwan University Hospital
- National Science and Technology Council
Zitieren
APA
Tang, S. C., Lin, S. Y., Chen, C. H., Liu, Y. B., Ho, L. T., Kuo, C. H., Peng, Y. F., Huang, C. F., & Jeng, J. S. (2026). Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70129
Vancouver
Tang SC, Lin SY, Chen CH, Liu YB, Ho LT, Kuo CH, et al. Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70129
BibTeX
@article{Tang2026,
author = {Tang, Sung-Chun and Lin, Shin-Yi and Chen, Chih-Hao and Liu, Yen-Bin and Ho, Li-Ting and Kuo, Ching-Hua and Peng, Yu-Fong and Huang, Chih-Fen and Jeng, Jiann-Shing},
title = {Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70129}
}
EUVIMED